Predict your next investment

Corporation
HEALTHCARE | Biotechnology
genebygene.com

See what CB Insights has to offer

Partners & Customers

1

About Gene by Gene

Gene By Gene provides reliable DNA testing to a wide range of consumer and institutional customers through its four divisions focusing on ancestry, health, research, and paternity. Gene By Gene provides DNA tests through its Family Tree DNA division. Gene by Gene is CLIA registered and through its clinical­health division, DNA Traits offers regulated diagnostic tests. DNA DTC is the Research Use Only (RUO) division serving both direct-­to-­consumer and institutional clients worldwide. Gene By Gene offers AABB certified relationship tests through its paternity testing division, DNA Findings. The company is headquartered in Houston, which is also home to its Genomics Research Center.On January 7th, 2021, Gene by Gene merged with myDNA.

Gene by Gene Headquarter Location

1445 North Loop West 820

Houston, Texas, 77008,

United States

(713) 474-2401

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Gene by Gene News

06:30 EDT Carrier Screening Market - 2022-2026 | Rising Prevalence of Genetic Diseases and Disorders to Boost Market Growth | 17...

Mar 16, 2022

| Rising Prevalence of Genetic Diseases and Disorders to Boost Market Growth | 17,000+ Technavio Research Reports News provided by Share this article Share this article Technavio has announced its latest market research report titled Carrier Screening Market by Type and Geography - Forecast and Analysis 2022-2026 The potential growth difference for the carrier screening market from 2021 to 2026 is USD 2.36  billion. To get the exact yearly growth variance and the Y-O-Y growth rate, Talk to our analyst . Key Market Dynamics: Market Driver The increased frequency of genetic illnesses and disorders such as cystic fibrosis, Tay-Sachs disease, and sickle cell anemia is one of the important reasons driving the worldwide carrier screening market growth. Prenatal testing has become more popular as the frequency of impairments in infants has increased, allowing doctors to swiftly treat treatable genetic abnormalities and diseases. According to the CDC, every year in the United States, one out of every 33 newborns (about 3%) is born with birth defects. Around the world, between 7 million and 9 million kids are born with birth disorders. Furthermore, parents with inheritable genetic illnesses such as autosomal dominant and recessive disorders prefer prenatal testing protocols for early disease detection. Market Challenges One of the significant carrier screening market trends that are projected to drive market expansion in the forecast period is the rising tendencies of next-generation sequencing (NGS) technology in carrier screening. NGS has advanced genetic research by allowing wide-scale sequencing of the human genome to find disease-causing mutations and gene variations of intermediate to large size. The carrier screening market report is segmented by Type (Expanded carrier screening and Targeted disease carrier screening) and Geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America will be the leading region with 37% of the market's growth during the forecast period. The US, Germany, UK, Japan, and China are the key market for carrier screening in North America. Growing concerns on early disease diagnosis, a significant rise in commercial approvals for advanced carrier screening, and the increasing use of pharmacogenomic testing will facilitate the carrier screening market growth in North America over the forecast period. The expanded carrier screening sector will gain a substantial amount of market share. Advancements in the extended carrier screening market, such as Sema4 Elements Expanded Carrier Screen (ECS) with Personalized Residual Risk solution from Sema4 OpCo, Inc, are likely to boost demand, resulting in segment growth throughout the projection period. View our sample report  for additional insights into the contribution of all the segments, and regional opportunities in the report. Some Companies Mentioned with their Offerings The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive in the market. The report analyzes the market's competitive landscape and offers information on several market vendors, including: Abbott Laboratories Fulgent Genetics MedGenome Labs Ltd. OPKO Health Inc. Companies profiled Abbott Laboratories, Agilent Technologies Inc., CENTOGENE NV, Danaher Corp., Eurofins Scientific SE, DiaSorin SpA, F. Hoffmann La Roche Ltd., Fulgent Genetics, Gene By Gene Ltd, Illumina Inc., Invitae Corp., Laboratory Corp. of America Holdings, MedGenome Labs Ltd., Myriad Genetics Inc., Natera Inc., OPKO Health Inc., Otogenetics Corporation, Quest Diagnostics Inc., Sema4 OpCo Inc., and Thermo Fisher Scientific Inc. Market Dynamics Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period. Customization purview If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. Table of Contents: Exhibit 27: Data Table on Comparison by Type 5.3 Expanded carrier screening - Market size and forecast 2021-2026 Exhibit 28: Chart on Expanded carrier screening - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Expanded carrier screening - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Expanded carrier screening - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Expanded carrier screening - Year-over-year growth 2021-2026 (%) 5.4 Targeted disease carrier screening - Market size and forecast 2021-2026 Exhibit 32: Chart on Targeted disease carrier screening - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Targeted disease carrier screening - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Targeted disease carrier screening - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Targeted disease carrier screening - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 Germany - Market size and forecast 2021-2026 Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.9 Japan - Market size and forecast 2021-2026 Exhibit 66: Chart on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Japan - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Japan - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Japan - Year-over-year growth 2021-2026 (%) 7.10 UK - Market size and forecast 2021-2026 Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.11 China - Market size and forecast 2021-2026 Exhibit 74: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on China - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers

Gene by Gene Acquisitions

1 Acquisition

Gene by Gene acquired 1 company. Their latest acquisition was Arpeggi on August 07, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/7/2013

Other

$99M

$0.19M

Acquired

1

Date

8/7/2013

Investment Stage

Other

Companies

Valuation

$99M

Total Funding

$0.19M

Note

Acquired

Sources

1

Gene by Gene Partners & Customers

1 Partners and customers

Gene by Gene has 1 strategic partners and customers. Gene by Gene recently partnered with BC Platforms on March 3, 2018.

Date

Type

Business Partner

Country

News Snippet

Sources

3/6/2018

Vendor

Switzerland

Gene By Gene Selects BC Platforms to enhance its world leading Genomic data processing services - BC Platforms

Gene By Gene Selects BC Platforms to enhance its world leading Genomic data processing services .

1

Date

3/6/2018

Type

Vendor

Business Partner

Country

Switzerland

News Snippet

Gene By Gene Selects BC Platforms to enhance its world leading Genomic data processing services - BC Platforms

Gene By Gene Selects BC Platforms to enhance its world leading Genomic data processing services .

Sources

1

Gene by Gene Team

5 Team Members

Gene by Gene has 5 team members, including current Chief Executive Officer, Lior Rauchberger.

Name

Work History

Title

Status

Dee G. Bardes

Founder

Current

Lior Rauchberger

Chief Executive Officer

Current

Doron M Behar MD PhD

Founder, Chief Medical Officer

Former

Jason Wang

Chief Technology Officer

Former

Michael Gugel

Senior Director

Former

Name

Dee G. Bardes

Lior Rauchberger

Doron M Behar MD PhD

Jason Wang

Michael Gugel

Work History

Title

Founder

Chief Executive Officer

Founder, Chief Medical Officer

Chief Technology Officer

Senior Director

Status

Current

Current

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.